DALLAS, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will join the American Burn Association (ABA) to promote practical, life-saving burn prevention strategies for workplaces of all types during this year’s National Burn Awareness Week. In support of this annual event, Spectral AI will host a ser ...

Core Insights - Spectral AI, Inc. reported its Q3 2025 financial results, highlighting a strong cash position of $10.5 million and a focus on advancing its De Novo FDA submission for its AI-driven diagnostic device in wound care [1][9][10] Financial Performance - Research and Development Revenue for Q3 2025 was $3.8 million, a decline of 54% from $8.2 million in Q3 2024, attributed to reduced costs related to the BARDA contract following the FDA submission [5][8] - Gross margin for Q3 2025 was 42.7%, down from 44.9% in Q3 2024, reflecting similar cost reductions [6] - General and administrative expenses increased to $5.0 million in Q3 2025 from $4.6 million in Q3 2024, due to higher consultant and service provider costs [7] - The company reported a net loss of $(3.6) million for Q3 2025, compared to a net loss of $(1.5) million in Q3 2024, primarily due to decreased revenue [8][18] Cash Position and Financing - As of September 30, 2025, the company's cash position improved to $10.5 million from $3.7 million in Q3 2024, remaining flat from Q2 2025 [10] - The company raised approximately $7.6 million through a securities purchase agreement for the sale of 3,065,000 shares at $1.90 per share, along with warrants and pre-funded warrants [3] Business Developments - The company is focused on commercializing its innovative diagnostic device to assist clinical decision-making, which may significantly improve patient outcomes [2] - The revenue guidance for FY 2025 has been reduced from $21.5 million to $18.5 million, reflecting timing issues with the BARDA contract and impacts from the US government shutdown [11]

Core Insights - Spectral AI, Inc. will report its financial results for Q3 2025 on November 11, 2025, after market close, followed by a conference call at 5:00 PM ET to discuss the results [1] Company Overview - Spectral AI is a Dallas-based predictive AI company focused on medical diagnostics, particularly in wound care, aiming for faster and more accurate treatment decisions [3] - The company is developing the DeepView® System, a predictive device designed to provide clinicians with an objective assessment of a burn wound's healing potential prior to treatment [3] - The DeepView System aims to improve patient outcomes and reduce healthcare costs by offering algorithm-driven results that exceed the current standard of care [3]

Core Insights - The article highlights the rapid growth of artificial intelligence (AI) in the healthcare sector, with significant advancements in AI applications for medical purposes [1][2][8] - Avant Technologies, Inc. is positioned as a key player in AI-driven healthcare innovation, particularly through its partnership with Ainnova Tech and the development of the Vision AI platform [3][5][8] AI in Healthcare - Dartmouth researchers conducted a clinical trial of a therapy chatbot powered by generative AI, showing significant symptom improvements in participants [1] - Bill Gates predicts that AI will democratize medical advice, making it free and widely accessible [2] - Layer Health raised $21 million to address scalability challenges in healthcare AI, indicating strong investor interest in this sector [2] Avant Technologies and Ainnova - Avant Technologies and Ainnova Tech are collaborating to present at the 2025 Healthcare Innovation Summit in Mexico City, focusing on digital transformation in healthcare [3][5] - Ainnova's CEO will discuss the impact of the Vision AI platform on early disease detection, with clinical trial protocols being designed for FDA submission [4][6] - The Vision AI platform has received commercial clearance in Brazil and is preparing for clinical pilots across the Americas [5] Regulatory and Market Position - Ainnova is working with global CRO Fortrea to seek FDA 510(k) clearance for Vision AI in detecting diabetic retinopathy, which could expand its use in chronic disease management [6][8] - Avant Technologies and Ainnova jointly control Ai-nova Acquisition Corp., which holds global licensing rights to a technology portfolio validated on over 2.3 million clinical data points [7] Other Industry Developments - Apple Inc. is developing an AI-driven health coach, potentially enhancing its Health app with features for diet and exercise guidance [9][10][11] - Amazon.com, Inc. is testing a health assistant chatbot called Health AI, which aims to provide medical guidance and connect users to its online pharmacy [12][13] - Spectral AI, Inc. reported strong results from its DeepView® System in a Burn Validation Study, aiming for FDA submission by mid-2025 [14][15] - GE HealthCare Technologies Inc. launched the Revolution™ Vibe CT system, featuring AI-powered cardiac imaging to improve diagnostic speed and patient comfort [16][17]

As filed with the Securities and Exchange Commission on January 23, 2024 Registration No. 333-276406 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________________________ AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 _____________________________________ Spectral AI, Inc. (Exact name of registrant as specified in its charter) _____________________________________ (State or other jurisdiction of incorporation or organization) (Prim ...